NEW YORK, November 19, 2025 – Shares of Nuvation Bio Inc. (NYSE: NUVB) exploded higher on Wednesday after B. Riley Securities initiated coverage with a bullish rating and a $12 price target, adding fresh fuel to a rally driven by the successful launch of the company’s lung cancer drug IBTROZI™ (taletrectinib) and a blockbuster third quarter. [1]
As of early afternoon on November 19, 2025, NUVB was trading around $7.1–$7.2, up roughly 50% on the day from Tuesday’s close near $4.80, on extremely heavy volume. The stock’s 52‑week range has expanded from about $1.54 at the low to over $7.3 at today’s high, lifting Nuvation’s market capitalization to roughly $2.4 billion. [2]
This surge comes on the same day management is presenting at the Jefferies Global Healthcare Conference in London, putting the fast‑moving oncology company squarely in front of a global institutional audience. [3]
NUVB stock today: price action and performance snapshot
According to intraday data from multiple market sources, NUVB: [4]
- Traded around $7.1–$7.2 in early afternoon on November 19, 2025
- Was up roughly $2.4 per share versus the prior close – an intraday move of about 50%
- Saw an intraday range stretching from just under $5 to more than $7.3
- Logged tens of millions of shares in volume, far above its typical daily turnover
- Carries a beta around 1.6, underscoring that this is a volatile biotech name
Earlier in the session, Investing.com reported that Nuvation Bio had broken out to a fresh 52‑week high at $5.57, with a market cap then around $1.8 billion, before the rally accelerated further as U.S. trading progressed. [5]
Over a longer horizon, the stock has already delivered an eye‑catching performance:
- Roughly +85% over the past 12 months
- Around +100–110% over the last six months, reflecting increasing optimism around IBTROZI and the broader pipeline [6]
What is driving Nuvation Bio stock today? Key news for 19 November 2025
1. B. Riley initiates NUVB with a “Buy” rating and $12 price target
The single biggest catalyst today is B. Riley Securities launching coverage on Nuvation Bio with a Buy rating and a $12 price target. [7]
Key points from the new coverage:
- The $12 target implies roughly 150% upside from the $4.80 reference price used in the report. [8]
- The call is heavily anchored in the commercial momentum of IBTROZI, Nuvation’s ROS1‑positive non‑small cell lung cancer (NSCLC) therapy.
- B. Riley highlights 204 new patient starts in Q3 2025, beating expectations in the drug’s first full commercial quarter. [9]
- The firm stresses IBTROZI’s profile as a highly selective, brain‑penetrant, next‑generation ROS1 tyrosine kinase inhibitor (TKI) with “high and durable response rates” observed in pivotal trials. [10]
The initiation joins an already bullish analyst backdrop. GuruFocus notes that B. Riley’s move adds to a cluster of positive ratings from firms including Citizens, RBC Capital, Wedbush, Jefferies and H.C. Wainwright, with recent price targets ranging from $7 to $10 before today’s new $12 high watermark. [11]
MarketBeat’s latest consensus shows 10 analysts covering NUVB with an overall “Moderate Buy” rating and an average 12‑month price target around $9.00, about 28% above where the stock trades after today’s spike. [12]
2. Shares rip to new highs; NUVB flagged among top movers
With B. Riley’s note hitting before the U.S. open, traders rushed into the stock. By midday, MarketScreener/MT Newswires had NUVB on its “Top Midday Gainers” list, citing a move of roughly +47% with intraday trading near $7.05. [13]
The rally builds on an already strong November:
- Just days ago, specialist outlets such as Parameter and Investing.com highlighted NUVB’s new 52‑week high at $5.57, noting that the stock had gained 85% over the past year and more than 100% in six months. [14]
Today’s additional 40–50% surge is effectively a momentum-on-momentum move, with short‑term traders, biotech specialists and generalist funds all reacting to the same bullish narrative: a rapidly scaling oncology franchise backed by increasingly optimistic Wall Street research.
3. Institutional buying – and some insider activity
While today’s move is analyst‑driven, ownership trends also matter for medium‑term investors.
A fresh report from MarketBeat, dated November 19, 2025, highlights that Los Angeles Capital Management LLC recently established a new position of 106,020 NUVB shares, valued at about $207,000 in Q2. The article notes that institutional investors now hold roughly 61.7% of Nuvation Bio’s float. [15]
The same filing summary points out that:
- An insider, Gary Hattersley, sold 100,000 shares at an average price of $5.02,
- Yet insiders as a group still control close to 30% of the company, signalling meaningful management skin in the game even after profit‑taking. [16]
For a small‑mid‑cap biotech, that combination – heavy institutional participation plus substantial insider ownership – often signals both professional interest and founder‑level conviction, even if insider selling adds a note of caution.
4. Investor‑relations push: Jefferies conference appearance today
Nuvation Bio’s leadership is also actively in front of investors this week. The company previously announced that CEO David Hung, M.D., and CFO Philippe Sauvage would appear at the Jefferies Global Healthcare Conference on Wednesday, November 19, 2025, at 10:00 a.m. ET / 3:00 p.m. GMT in London. [17]
That appearance, along with additional upcoming conferences later in the year, is part of a broader strategy to:
- Showcase the IBTROZI launch trajectory
- Update investors on the Phase 3 TRUST‑IV adjuvant trial and other pipeline programs
- Reinforce the narrative that Nuvation is transitioning from a development‑stage biotech to a commercial‑stage oncology company
The timing is fortuitous: management is presenting just as the stock is making new highs and a high‑profile bank has entered the bull camp.
Fundamentals behind the headline move: Q3 2025 beat and explosive revenue growth
While today’s price action is dramatic, it rests on concrete fundamental developments from Q3 2025.
In early November, Nuvation Bio reported that Q3 2025 revenue reached approximately $13.1 million, far above Wall Street expectations of around $6.6–$6.8 million – a revenue beat of roughly 90–95%. [18]
The revenue mix underscores the dual nature of Nuvation’s business model:
- About $7.7 million in U.S. net product revenue from IBTROZI in its first full commercial quarter
- Roughly $5.4 million from collaboration and license agreements, largely driven by its partnerships in Japan (Nippon Kayaku) and China (Innovent) [19]
Other Q3 highlights:
- 204 new patient starts on IBTROZI in the quarter, exceeding internal and Street expectations for a launch in a relatively small genomic subset of NSCLC [20]
- A net loss of about $55–56 million (–$0.16 per share), reflecting continued investment in R&D and commercialization [21]
- A cash and marketable securities balance around $550 million, supported in part by a $250 million non‑dilutive financing deal earlier in 2025, providing a multiyear runway to fund development and launch activities [22]
On a trailing 12‑month basis, various data providers estimate Nuvation’s revenue at roughly $26–27 million, implying very high price‑to‑sales multiples (around 90x) at today’s market cap – typical for promising oncology names where investors are discounting many years of potential growth. [23]
IBTROZI (taletrectinib): the lung cancer drug powering the story
At the heart of Nuvation’s surge is IBTROZI™ (taletrectinib), a next‑generation ROS1 inhibitor for adults with locally advanced or metastatic ROS1‑positive NSCLC.
Regulatory and commercial status
- U.S. FDA approval: In June 2025, IBTROZI received U.S. approval for adult ROS1‑positive NSCLC following Priority Review and Breakthrough Therapy Designations in both first‑line and later‑line settings. [24]
- Japan: Partner Nippon Kayaku obtained approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for IBTROZI in advanced ROS1+ NSCLC, triggering expectations for a $25 million milestone payment to Nuvation once reimbursement is finalized. [25]
- China and global trials: IBTROZI has been studied across the TRUST‑I (China) and TRUST‑II (global) Phase 2 programs and is being expanded in TRUST‑III and TRUST‑IV Phase 3 trials, including an adjuvant setting in early‑stage disease. [26]
Nuvation has also opened an expanded access program in the U.S. for eligible patients, designed to broaden availability while the company continues to generate data and pursue label enhancements. [27]
Clinical data: high responses and strong brain activity
Updated data presented at the 2025 World Conference on Lung Cancer (WCLC) continue to support the bullish view around IBTROZI’s efficacy, especially in the difficult setting of brain metastases: [28]
- In TKI‑naïve TRUST‑I patients (n=103):
- Confirmed objective response rate (cORR) was about 90%
- Median progression‑free survival (PFS) was around 44.6 months
- Median duration of response (DOR) had not yet been reached; the longest observed response was ~47 months and ongoing
- About 88% of patients with brain metastases experienced intracranial tumor shrinkage
- In TKI‑pretreated patients, cORR remained robust (roughly 50–60% across TRUST‑I and TRUST‑II), with meaningful PFS and DOR and substantial intracranial activity in patients with brain lesions.
Safety data from pooled analyses show a manageable safety profile with expected class‑related toxicities such as liver enzyme elevations and QT prolongation, but relatively low discontinuation rates when managed appropriately. [29]
Taken together, these results underpin analysts’ comparisons between IBTROZI and earlier generation targeted therapies that went on to become multi‑billion‑dollar franchises in other mutation‑defined lung cancers.
Beyond IBTROZI: Nuvation Bio’s broader oncology pipeline
Although IBTROZI is the primary commercial driver today, Nuvation is positioning itself as a platform oncology company with several additional assets: [30]
- Safusidenib (IDH1 inhibitor)
- Brain‑penetrant agent being evaluated in high‑grade IDH1‑mutant glioma in the G203 study, with protocol amendments intended to support a potential path to registration as a maintenance therapy.
- Nuvation is also exploring expansion into subsets of low‑grade IDH1‑mutant gliomas.
- NUV‑1511 (drug‑drug conjugate / DDC platform)
- A novel “drug‑drug conjugate” designed to deliver targeted cancer therapy; management has guided that additional data updates are planned by year‑end 2025, a catalyst investors are watching closely. [31]
- NUV‑868 (BD2‑selective BET inhibitor)
- A next‑generation epigenetic therapy in clinical development, with potential to be paired with other agents in difficult‑to‑treat tumors.
These pipeline elements add optionality to the NUVB story: while IBTROZI anchors near‑term revenue, success in glioma, DDCs or BET inhibition could materially expand the company’s addressable market over the next several years.
Valuation snapshot: what today’s move may (and may not) be pricing in
After today’s rally, Nuvation Bio trades at levels that reflect significant expectations:
- Market cap: ≈ $2.4 billion at ~$7.1–7.2 per share
- Trailing 12‑month revenue: ≈ $26–27 million, implying a price‑to‑sales multiple around 90x
- Consensus 12‑month price target: about $9.00, with a range from $6 (bearish) to $12 (B. Riley’s high end), suggesting analysts still see ~25–30% upside from current levels on average. [32]
For context:
- A high P/S multiple is not unusual for a newly commercial oncology name with strong early data and a small but growing launch.
- However, it also means a lot is already baked into the price: markets are implicitly assuming continued uptake of IBTROZI, successful geographic expansion, favorable reimbursement decisions and progressing pipeline milestones.
Investors should also remember that:
- Nuvation remains loss‑making, with quarterly net losses in the tens of millions of dollars as it funds Phase 3 programs and commercial infrastructure. [33]
- The stock’s beta above 1.5 and history of sharp swings (from a 52‑week low around $1.54 to over $7 today) underline that NUVB is high‑volatility, high‑risk even by biotech standards. [34]
Key risks and what to watch next
For readers following Nuvation Bio after today’s fireworks, several near‑term milestones and risks stand out:
Catalysts to watch
- Commercial metrics for IBTROZI: future earnings reports will show whether the 204 Q3 patient starts are a baseline or an early spike. [35]
- Japanese reimbursement decision and $25M milestone from Nippon Kayaku. [36]
- China reimbursement (NRDL) prospects and the progress of TRUST‑III and TRUST‑IV Phase 3 studies. [37]
- Data updates from safusidenib, NUV‑1511 and NUV‑868, which could broaden the company’s value proposition beyond ROS1+ NSCLC. [38]
Key risks
- Clinical and regulatory risk: failures or delays in late‑stage trials (TRUST‑IV, glioma studies, etc.) could materially impact the long‑term thesis. [39]
- Safety and label evolution: ROS1 TKIs, including IBTROZI, carry class warnings (liver toxicity, ILD/pneumonitis, QT prolongation), and unexpected safety signals could limit use or trigger label changes. [40]
- Commercial competition: Nuvation competes against other ROS1 inhibitors and future entrants; superior or cheaper alternatives could slow IBTROZI adoption.
- Valuation and volatility: after such a rapid re‑rating, even small disappointments can lead to large drawdowns in high‑beta biotech stocks.
Bottom line
Nuvation Bio’s huge move on November 19, 2025 is not just a meme‑style spike – it rests on tangible clinical data, a better‑than‑expected drug launch and a drumbeat of increasingly bullish analyst coverage, capped today by B. Riley’s $12 price target and Buy rating. [41]
At the same time, the stock now trades on rich expectations, with a valuation that assumes IBTROZI will continue to scale and that at least some of Nuvation’s broader oncology pipeline will come through. That combination – real progress plus elevated risk – is typical of emerging biotech leaders and is exactly why NUVB is drawing so much attention across Wall Street and trading desks today.
Important: This article is for information and news purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or a substitute for your own research and professional financial guidance.
References
1. m.investing.com, 2. stockanalysis.com, 3. investors.nuvationbio.com, 4. stockanalysis.com, 5. www.investing.com, 6. parameter.io, 7. m.investing.com, 8. m.investing.com, 9. m.investing.com, 10. m.investing.com, 11. www.gurufocus.com, 12. www.marketbeat.com, 13. www.marketscreener.com, 14. parameter.io, 15. www.marketbeat.com, 16. www.marketbeat.com, 17. investors.nuvationbio.com, 18. www.businesswire.com, 19. www.businesswire.com, 20. www.businesswire.com, 21. www.businesswire.com, 22. www.businesswire.com, 23. stockanalysis.com, 24. investors.nuvationbio.com, 25. finviz.com, 26. www.businesswire.com, 27. investors.nuvationbio.com, 28. investors.nuvationbio.com, 29. investors.nuvationbio.com, 30. investors.nuvationbio.com, 31. www.businesswire.com, 32. stockanalysis.com, 33. www.businesswire.com, 34. stockanalysis.com, 35. www.businesswire.com, 36. finviz.com, 37. www.businesswire.com, 38. www.businesswire.com, 39. investors.nuvationbio.com, 40. investors.nuvationbio.com, 41. m.investing.com
